Great Point Partners’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-530,670
| Closed | -$49.3M | – | 41 |
|
|
2021
Q4 | $49.3M | Hold |
530,670
| – | – | 10.96% | 1 |
|
|
2021
Q3 | $31.6M | Buy |
530,670
+25,000
| +5% | +$1.48M | 7.36% | 2 |
|
|
2021
Q2 | $34.5M | Buy |
505,670
+129,800
| +35% | +$8.46M | 7.23% | 3 |
|
|
2021
Q1 | $26.1M | Buy |
375,870
+30,750
| +9% | +$2.37M | 5.39% | 8 |
|
|
2020
Q4 | $26.5M | Sell |
345,120
-651,778
| -65% | -$48.9M | 4.31% | 11 |
|
|
2020
Q3 | $74.6M | Sell |
996,898
-305,501
| -23% | -$20.4M | 6.71% | 4 |
|
|
2020
Q2 | $82M | Buy |
1,302,399
+914,900
| +236% | +$50.3M | 6.55% | 6 |
|
|
2020
Q1 | $16.3M | Buy |
+387,499
| New | +$17.8M | 1.7% | 19 |
|
|
2018
Q3 | – | Sell |
-302,000
| Closed | -$13.2M | – | 42 |
|
|
2018
Q2 | $13.2M | Sell |
302,000
-1,003,887
| -77% | -$43.1M | 1.82% | 21 |
|
|
2018
Q1 | $51.6M | Buy |
1,305,887
+128,768
| +11% | +$5.01M | 7.66% | 2 |
|
|
2017
Q4 | $40M | Sell |
1,177,119
-180,681
| -13% | -$5.15M | 6.82% | 2 |
|
|
2017
Q3 | $34.6M | Sell |
1,357,800
-1,082,130
| -44% | -$24.8M | 6.74% | 3 |
|
|
2017
Q2 | $41.2M | Buy |
+2,439,930
| New | +$33.5M | 7.37% | 1 |
|
Great Point Partners's ARNA Position: Q1 2022 in Review
Great Point Partners sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 530,670 shares — an estimated $49.3M sold.
Great Point Partners first reported a position in ARNA in Q2 2017 and held it in 13 quarters. The position peaked at $82M in Q2 2020. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Great Point Partners reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Great Point Partners sold 530,670 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $49.3M.
- Great Point Partners first reported a position in Arena Pharmaceuticals Inc in Q2 2017 and held it in 13 quarters.
- Great Point Partners's Arena Pharmaceuticals Inc position peaked at $82M in Q2 2020.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Great Point Partners's 13F filing for Q1 2022, filed 16 May 2022.